Tretinoin (Topical)
Brand names: Retin-A, Retrieve, Acnecide (different ingredient)
A topical retinoid (all-trans retinoic acid) used in the treatment of acne vulgaris, particularly comedonal acne, and applied to the skin as a cream or gel.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Tretinoin binds nuclear retinoic acid receptors to normalise follicular keratinocyte differentiation and reduce abnormal cohesion of corneocytes, preventing microcomedone formation and promoting expulsion of existing comedones.
Prescribing in practice
- Topical retinoids are contraindicated in pregnancy and should be avoided in women planning pregnancy, with effective contraception advised during use.
- It commonly causes skin irritation, dryness, erythema and peeling, and increases photosensitivity, so daytime sun protection and avoidance of UV/sunbeds are important.
- An initial apparent worsening of acne can occur before improvement, and concurrent use of harsh or abrasive skin products should be avoided.
Monitoring
No laboratory monitoring is required; review tolerability and acne response, adjusting frequency of application if irritation is excessive.
Counselling the patient
- Apply a thin amount to clean, dry skin at night and use a daytime sunscreen.
- Expect some dryness, redness and peeling initially; reduce frequency if too irritating and allow several weeks for benefit.
- Do not use if pregnant or trying to conceive.
Evidence & guidelines
Topical retinoids such as tretinoin are recommended by NICE as a core component of topical acne treatment, often combined with benzoyl peroxide or a topical antibiotic.
Reference: BAD Acne Guidelines 2020; Kligman et al. (1986) Retin-A photoaging; NICE NG198 (Acne); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD